CompletedNCT06273774
A Study of Elpipodect (MK-8189) in Participants With Bipolarity type I (MK-8189-020)
Medication studyAges 18–60United States
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: April 8, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT06273774
- Official title
Show the full official title
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
Get this study by email
Recruitment & locations
CompletedLittle Rock · Atlanta · Marlton
Questions about this study
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Did this study involve medication?
Yes. The study involved medication, including Elpipodect and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
